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The importance of early treatment with tranexamic acid in 
bleeding trauma patients: an exploratory analysis of the 
CRASH-2 randomised controlled trial
The CRASH-2 collaborators*
Summary 
Background The aim of the CRASH-2 trial was to assess the eﬀ ects of early administration of tranexamic acid on 
death, vascular occlusive events, and blood transfusion in trauma patients with signiﬁ cant haemorrhage. Tranexamic 
acid signiﬁ cantly reduced all-cause mortality. Because tranexamic acid is thought to exert its eﬀ ect through inhibition 
of ﬁ brinolysis, we undertook exploratory analyses of its eﬀ ect on death due to bleeding.
Methods The CRASH-2 trial was undertaken in 274 hospitals in 40 countries. 20 211 adult trauma patients with, or 
at risk of, signiﬁ cant bleeding were randomly assigned within 8 h of injury to either tranexamic acid (loading dose 
1 g over 10 min followed by infusion of 1 g over 8 h) or placebo. Patients were randomly assigned by selection of 
the lowest numbered treatment pack from a box containing eight numbered packs that were identical apart from 
the pack number. Both participants and study staﬀ  (site investigators and trial coordinating centre staﬀ ) 
were masked to treatment allocation. We examined the eﬀ ect of tranexamic acid on death due to bleeding 
according to time to treatment, severity of haemorrhage as assessed by systolic blood pressure, Glasgow 
coma score (GCS), and type of injury. All analyses were by intention to treat. The trial is registered as 
ISRCTN86750102, ClinicalTrials.gov NCT00375258, and South African Clinical Trial Register/Department of 
Health DOH-27-0607-1919.
Findings 10 096 patients were allocated to tranexamic acid and 10 115 to placebo, of whom 10 060 and 10 067, 
respectively, were analysed. 1063 deaths (35%) were due to bleeding. We recorded strong evidence that the eﬀ ect of 
tranexamic acid on death due to bleeding varied according to the time from injury to treatment (test for interaction 
p<0·0001). Early treatment (≤1 h from injury) signiﬁ cantly reduced the risk of death due to bleeding 
(198/3747 [5·3%] events in tranexamic acid group vs 286/3704 [7·7%] in placebo group; relative risk [RR] 0·68, 
95% CI 0·57–0·82; p<0·0001). Treatment given between 1 and 3 h also reduced the risk of death due to bleeding 
(147/3037 [4·8%] vs 184/2996 [6·1%]; RR 0·79, 0·64–0·97; p=0·03). Treatment given after 3 h seemed to increase 
the risk of death due to bleeding (144/3272 [4·4%] vs 103/3362 [3·1%]; RR 1·44, 1·12–1·84; p=0·004). We recorded 
no evidence that the eﬀ ect of tranexamic acid on death due to bleeding varied by systolic blood pressure, Glasgow 
coma score, or type of injury.
Interpretation Tranexamic acid should be given as early as possible to bleeding trauma patients. For trauma patients 
admitted late after injury, tranexamic acid is less eﬀ ective and could be harmful.
Funding UK NIHR Health Technology Assessment programme, Pﬁ zer, BUPA Foundation, and J P Moulton 
Charitable Foundation.
Introduction
The CRASH-2 trial showed that administration of 
tranexamic acid to adult trauma patients with, or at risk 
of, signiﬁ cant haemorrhage, within 8 h of injury, 
signi ﬁ cantly reduces all-cause mortality (relative risk 
[RR] 0·91, 95% CI 0·85–0·97; p=0·0035) with no apparent 
increase in vascular occlusive events.1 As a consequence 
of this trial, tranexamic acid has been incorporated into 
trauma treatment protocols worldwide.
Results from the CRASH-2 trial raise some important 
questions. The trial was motivated by the evidence that 
tranexamic acid reduces bleeding in patients undergoing 
elective surgery, and the hypothesised mechanism 
was inhibition of ﬁ brinolysis leading to improved 
eﬀ ectiveness of haemostasis.2 However, no signiﬁ cant 
diﬀ erence was recorded in transfusion requirements 
between the tranexamic acid and placebo groups, and 
the CRASH-2 trial did not measure the eﬀ ect of this 
drug on ﬁ brinolytic assays. Thus an alternative hypo-
thesis is that tranexamic acid might act by reducing the 
pro-inﬂ ammatory eﬀ ects of plasmin, rather than by 
improving haemostasis.3
There has also been discussion about which trauma 
patients should be treated with tranexamic acid. The 
CRASH-2 trial1 reported the few subgroup analyses that 
were prespeciﬁ ed in the statistical analysis plan. These 
analyses assessed the eﬀ ect of tranexamic acid on the 
primary endpoint of all-cause mortality, according to 
time since injury, systolic blood pressure, Glasgow coma 
score, and type of injury. No strong evidence of 
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heterogeneity was recorded for any of these analyses, 
suggesting that tranexamic acid is likely to be equally 
eﬀ ective in all the subgroups examined.
The focus on all-cause mortality was appropriate 
because it is an outcome that matters to patients and one 
that is not aﬀ ected by the methodological problem of 
competing risks.4 However, the eﬀ ect of the trial treatment 
on the biologically relevant outcome could have been 
diluted by outcomes on which tranexamic acid might 
have little or no eﬀ ect. In response to these concerns, we 
undertook exploratory analyses of the eﬀ ect of tranexamic 
acid on mortality due to bleeding. We report the same 
prespeciﬁ ed subgroup analyses but for the outcome that 
we hypothesise would be most aﬀ ected by this drug, 
speciﬁ cally mortality due to bleeding.
Methods
Study design and patients
The background to the trial, methods, and baseline 
characteristics of the randomised patients have been 
previously reported.1 Brieﬂ y, we randomly allocated 
20 211 adult trauma patients with, or at risk of, 
signiﬁ cant bleeding who were within 8 h of injury to 
either tranexamic acid (loading dose 1 g over 10 min 
followed by infusion of 1 g over 8 h) or matching 
placebo, with 99·6% follow-up. In most hospitals we 
used a local pack system for randomisation. After 
eligibility had been conﬁ rmed and the locally approved 
consent procedures had been completed, patients were 
randomly assigned by selection of the lowest numbered 
treatment pack from a box containing eight numbered 
packs. Apart from the pack number, the treatment 
packs were identical. The pack number was recorded 
on the entry form, which was sent to the Trial 
Coordinating Centre in London, UK. Hospitals with 
telephone access used a telephone randomisation 
service. Both participants and study staﬀ  (site 
investigators and trial coordinating centre staﬀ ) were 
masked to treatment allocation.
Statistical analysis
The primary outcome was death in hospital within 
4 weeks of injury, with cause of death described with the 
following categories: bleeding, vascular occlusion 
(myocardial infarction, stroke, and pulmonary embolism), 
multiorgan failure, head injury, and other.
All analyses were by intention to treat. We examined 
the eﬀ ect of the trial treatment on death due to bleeding 
subdivided by four baseline characteristics: (1) time from 
injury to treatment (≤1, >1–3, >3 h); (2) severity of 
haemorrhage as assessed by systolic blood pressure (≤75, 
76–89, >89 mm Hg); (3) Glasgow coma score (severe 3–8, 
moderate 9–12, mild 13–15); and (4) type of injury 
(penetrating only, blunt plus blunt and penetrating). 
These were the same subgroup analyses that were 
reported previously, but for the outcome of death due to 
bleeding rather than for all-cause mortality.
Heterogeneity in treatment eﬀ ects across subgroups 
was assessed by a χ² test. We had prespeciﬁ ed that unless 
there was strong evidence against the null hypothesis of 
homogeneity of eﬀ ects (ie, p<0·001), the overall RR 
would be considered the most reliable guide to the 
approximate RRs in all subgroups. To test the 
N All causes of death Bleeding death Non-bleeding death 
Overall 20 127 0·91 (0·85–0·97); 
p=0·0035
0·85 (0·76–0·96); 
p=0·0077
0·94 (0·86–1·02); 
p=0·13
Time to treatment (h)
≤1 7451 0·87 (0·76–0·97) 0·68 (0·57–0·82) 1·04 (0·89–1·21)
>1–3 6033 0·87 (0·77–0·97) 0·79 (0·64–0·97) 0·91 (0·78–1·05)
>3 6634 1·00 (0·90–1·13) 1·44 (1·12–1·84) 0·89 (0·78–1·02)
χ² test of homogeneity ·· 4·411 (p=0·11) 23·516 (p=0·0000) 2·537 (p=0·28)
Table 1: Relative risk (95% CI) of death with tranexamic acid, overall and by time to treatment
≤1 h (n=7451) >1–3 h (n=6033) >3 h (n=6634)
Age (years)
Mean (SD) 33·4 (13·9) 35·0 (14·0) 35·5 (14·8)
<25 2283 (30·6%) 1557 (25·8%) 1773 (26·7%)
25–34 2360 (31·7%) 1832 (30·4%) 1882 (28·4%)
35–44 1356 (18·2%) 1177 (19·5%) 1262 (19·0%)
>44 1452 (19·5%) 1467 (24·3%) 1716 (25·9%)
Systolic blood pressure (mm Hg)
≤75 1380 (18·5%) 1012 (16·8%) 768 (11·6%)
76–89 1203 (16·1%) 1064 (17·6%) 1029 (15·5%)
>89 4857 (65·2%) 3955 (65·6%) 4821 (72·7%)
Heart rate (beats per min)
<77 681 (9·1%) 450 (7·5%) 603 (9·1%)
77–91 1189 (16·0%) 971 (16·1%) 1326 (20·0%)
92–107 1888 (25·3%) 1562 (25·9%) 1625 (24·5%)
>107 3637 (48·8%) 2990 (49·6%) 3059 (46·1%)
Respiratory rate (breaths per min)
<10 149 (2·0%) 82 (1·4%) 77 (1·2%)
10–29 6144 (82·5%) 4992 (82·7%) 5590 (84·3%)
>29 1077 (14·5%) 901 (14·9%) 923 (13·9%)
Capillary reﬁ ll time (s)
≤2 2450 (32·9%) 2140 (35·5%) 2217 (33·4%)
3–4 3472 (46·6%) 2773 (46·0%) 3110 (46·9%)
>4 1131 (15·2%) 963 (16·0%) 1257 (19·0%)
Glasgow coma score
Severe (3–8) 1000 (13·4%) 1124 (18·6%) 1494 (22·5%)
Moderate (9–12) 868 (11·7%) 915 (15·2%) 909 (13·7%)
Mild (13–15) 5577 (74·9%) 3994 (66·2%) 4214 (63·5%)
Continents
Asia 1213 (16·3%) 2475 (41·0%) 3656 (55·1%)
Africa 2490 (33·4%) 1437 (23·8%) 872 (13·1%)
Central and South America 2453 (32·9%) 1456 (24·1%) 1355 (20·4%)
North America, Europe, and Oceania 1295 (17·4 %) 665 (11·0%) 751 (11·3%)
Data are number (%), unless otherwise stated.
Table 2: Patient characteristics by time to treatment
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independence of any observed treatment interactions we 
ran a logistic model including all possible interactions in 
the four prespeciﬁ ed baseline characteristics and 
treatment subgroups.
A logistic regression was estimated with death due to 
bleeding as the dependent variable and treatment group 
and time to treatment as explanatory factors. We included 
an interaction parameter to allow for a proportional change 
in the odds ratio (OR) as time to treatment increases. ORs 
and 95% CIs were estimated for diﬀ erent times to 
treatment. CIs were calculated with a logistic model with 
time as a continuous term and an interaction term between 
time and tranexamic acid.  We also ran a model with an 
interaction term for time to treatment squared to allow for 
a non-constant proportional change in the OR.
The trial is registered as ISRCTN86750102, 
ClinicalTrials.gov NCT00375258, and South African 
Clinical Trial Register/Department of Health DOH-27-
0607-1919.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author (IR) had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Of the 3076 deaths from all causes, death due to bleeding 
accounted for 1063 (35%). The risk of death due to 
bleeding was signiﬁ cantly reduced with tranexamic acid. 
489 of 10 060 (4·9%) patients died because of bleeding in 
the tranexamic acid group versus 574 of 10 067 (5·7%) in 
the placebo group (RR 0·85, 95% CI 0·76–0·96; 
p=0·0077). We noted no signiﬁ cant eﬀ ect on the risk of 
death for all other (non-bleeding) causes combined 
(table 1).
Table 2 shows the baseline characteristics of patients 
according to time to treatment. Figure 1 shows the 
results of the subgroup analyses for death due to 
bleeding. Time to treatment was unknown in nine 
participants. Treatment given 1 h or less from injury 
signiﬁ cantly reduced the risk of death due to bleeding 
(198/3747 [5·3%] in tranexamic acid group vs 286/3704 
[7·7%] in placebo group; RR 0·68, 95% CI 0·57–0·82; 
p<0·0001). Treatment given between 1 and 3 h also 
reduced the risk of death due to bleeding (147/3037 
[4·8%] vs 184/2996 [6·1%]; RR 0·79, 0·64–0·97; p=0·03). 
Treatment given more than 3 h after injury signiﬁ cantly 
increased the risk of death due to bleeding (144/3272 
[4·4%] vs 103/3362 [3·1%]; RR 1·44, 1·12–1·84; p=0·004). 
We recorded strong evidence that the eﬀ ect of 
tranexamic acid on death due to bleeding varied 
according to time from injury to treatment (p<0·0001). 
The evidence for interaction remained strong even after 
adjustment for interactions between the other 
prespeciﬁ ed baseline characteristics and treatment 
(p<0·0001; data not shown).
The estimated OR of tranexamic acid on death due to 
bleeding when given immediately after injury was 0·61 
Figure 1: Mortality due to bleeding by subgroups
Tranexamic acid allocated Placebo allocated Risk ratio (95% CI)
Time to treatment (h)
≤1
>1–3
>3
χ²=23·516; p<0·0000
Systolic blood pressure (mm Hg)
>89
76–89
≤75
χ²=2·235; p=0·33
Glasgow coma score
Severe (3–8)
Moderate (9–12)
Mild (13–15)
χ²=1·275; p=0·53
Type of injury
Blunt
Penetrating
χ²=0·923; p=0·34
All deaths
Two-sided p=0·0077
 198/3747 (5·3%)
 147/3037 (4·8%)
 144/3272 (4·4%)
 146/6878 (2·1%)
 110/1609 (6·8%)
 233/1562 (14·9%)
 168/1789 (9·4%)
 93/1349 (6·9%)
 228/6915 (3·3%)
 308/6788 (4·5%)
 181/3272 (5·5%)
 489/10 060 (4·9%)
286/3704 (7·7%)
184/2996 (6·1%)
103/3362 (3·1%)
163/6761 (2·4%)
114/1689 (6·7%)
295/1599 (18·4%)
186/1830 (10·2%)
121/1344 (9·0%)
265/6877 (3·8%)
347/6817 (5·1%)
227/3250 (7·0%)
574/10 067 (5·7%)
0·68 (0·57–0·82)
0·79 (0·64–0·97)
1·44 (1·12–1·84)
0·88 (0·71–1·10)
1·01 (0·79–1·30)
0·81 (0·69–0·95)
0·92 (0·76–1·13)
0·77 (0·59–0·99)
0·86 (0·72–1·02)
0·89 (0·77–1·04)
0·79 (0·66–0·96)
0·85 (0·76–0·96)
10·6 1·60·8 1·2 1·4
Tranexamic acid better Tranexamic acid worse
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(95% CI 0·50–0·74). We estimated that this OR is 
multiplied by 1·15 (95% CI 1·08–1·23) for every hour 
that passes since the injury. Figure 2 shows how the OR 
and 95% CIs vary with time to treatment. The interaction 
term for time to treatment squared was not signiﬁ cant 
(OR=0·99; p=0·38).
We recorded no evidence of heterogeneity for the 
subgroup analyses according to systolic blood pressure, 
Glasgow coma score at randomisation, or type of injury 
(ﬁ gure 1). We detected no evidence of heterogeneity in 
the eﬀ ect of tranexamic acid on the risk of non-bleeding 
deaths (table 1).
Discussion
The eﬀ ect of tranexamic acid on death due to bleeding 
depends on the time between injury and onset of 
treatment. Early treatment with this drug seems to be 
much more eﬀ ective than does late treatment. These 
results also raise the possibility that late treatment with 
tranexamic acid might increase the risk of death due to 
bleeding, although there was no evidence of any 
increase in all-cause mortality in patients treated after 
3 h (table 1). This ﬁ nding might indicate that patients 
treated with tranexamic acid beyond 3 h who died from 
bleeding might otherwise have died from some other 
non-bleeding cause (competing risks). If late admin-
istration does cause harm, this ﬁ nding would be 
important since many bleeding trauma patients in low-
income and middle-income countries have long 
prehospital times. Indeed, about a third of trauma 
patients in the CRASH-2 trial were treated more than 
3 h after the injury.
The inclusion criteria in the CRASH-2 trial were 
entirely clinical, and reﬂ ect the situation that doctors are 
faced with in clinical practice. Patients were enrolled if 
the treating physician judged them to have ongoing 
signiﬁ cant haemorrhage, as evidenced by hypotension or 
tachycardia, or if they were considered to be at risk of 
signiﬁ cant haemorrhage. Some of the included patients 
might not have been actively bleeding. Any such 
misdiagnosis would have reduced the power of the trial 
to show an eﬀ ect of tranexamic acid on mortality from 
bleeding, in which case the large and highly signiﬁ cant 
reduction in bleeding mortality in patients treated with 
this drug within 1 h of injury is particularly noteworthy.
Because patients were randomly assigned soon after 
hospital admission, before the precise anatomical 
location of bleeding and other injury was known, we 
were unable to do a stratiﬁ ed analysis based on an 
anatomical assessment of injury severity. We acknowledge 
that this omission is a methodological weakness, since 
such an analysis might provide insight into the 
mechanism of action of tranexamic acid. However, since 
this information would not normally be available to 
treating clinicians, especially in view of the importance 
of early treatment, the clinical value of a stratiﬁ ed analysis 
based on anatomical injury severity is small.
Data for the time between injury and treatment were 
available for all but nine trial participants. Because in 
some cases the injury would not have been witnessed, 
this interval sometimes had to be estimated and might 
therefore be inaccurate. However, any inaccuracy would 
be independent of the trial treatment and therefore 
should not bias the results. The ascertainment of a death 
as a bleeding death might also have been inaccurate, but 
similarly any inaccuracy should be independent of the 
trial treatment.
In clinical trials, a treatment is not often beneﬁ cial in 
one subgroup but harmful in another (qualitative 
interaction), and some trialists recommend that 
qualitative interactions should generally be disbelieved.5 
The results of our analysis of the eﬀ ect of tranexamic 
acid on death due to bleeding do, however, satisfy most of 
the criteria against which the credibility of subgroup 
results should be judged:6 time from injury was measured 
at baseline; the hypothesis that early treatment with 
tranexamic acid might be more eﬀ ective was prespeciﬁ ed 
in the trial protocol; the interaction suggests a very low 
likelihood that chance explains the ﬁ ndings; the 
interaction remained signiﬁ cant after controlling for the 
non-signiﬁ cant interactions between treatment and the 
other prespeciﬁ ed baseline prognostic factors; the 
subgroup eﬀ ect is large; and a biological rationale 
supports the interaction. Although this clinical trial was 
not powered to examine subgroup eﬀ ects, the interaction 
recorded is large and highly signiﬁ cant.7
Nevertheless, we prespeciﬁ ed in our trial protocol that 
the main subgroup analyses would be undertaken for all-
cause mortality, and not for mortality due to bleeding. 
Even though we postulated that tranexamic acid would 
act by reducing bleeding, we focused on all-cause 
mortality because overall survival is most important to 
patients. However, in view of the signiﬁ cant reduction in 
all-cause mortality, most of which was attributable to the 
eﬀ ect of tranexamic acid on death due to bleeding, and 
the biological rationale that this drug would act by 
Figure 2: Eﬀ ect of tranexamic acid on death due to bleeding by time 
to treatment
Shaded area shows 95% CI. OR=odds ratio.
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improving haemostasis, our analyses, although not 
prespeciﬁ ed, would seem justiﬁ ed.
Acute severe trauma is associated with increased 
ﬁ brinolysis that contributes to an early coagulopathy and 
increased mortality.8,9 Fibrinolysis can be assessed by 
measurement of ﬁ brin degradation products, which 
include small protein fragments called D-dimers. Brohi 
and colleagues8 showed that D-dimer concentrations are 
raised in trauma patients at the time of hospital admission 
(median prehospital time 28 min), with the highest 
concentrations measured in the most severely injured 
patients.8 Similar results were recorded in a 2009 study 
from Japan that measured ﬁ brin degradation product 
and D-dimers in 314 severe trauma patients.10 If this early 
increased ﬁ brinolysis exacerbates bleeding and increases 
the risk of death, then we might expect that an 
antiﬁ brinolytic drug such as tranexamic acid would be 
most eﬀ ective in this period.
Although we had anticipated that early treatment with 
tranexamic acid might be most eﬀ ective, the apparent 
increase in the risk of death due to bleeding in patients 
treated more than 3 h after the injury is unexpected and 
cannot readily be explained. It could be a chance ﬁ nding 
and there might be no real biological eﬀ ect. However, 
patients in the late phase of trauma can develop 
thrombotic disseminated intravascular coagulation, 
and antiﬁ brinolytics could be contraindicated in this 
period.10,11 Although disseminated intravascular coagu-
lation is characterised by ﬁ brin formation and 
coagulation, the rapid consumption of coagulation 
proteins can lead to their exhaustion, resulting in 
uncontrolled bleeding. The need to avoid giving an 
antiﬁ brinolytic in this late phase was why we restricted 
trial inclusion to patients who were within 8 h of 
injury. The possibility that the change to a prothrombotic 
state might occur sooner than was previously expected 
is open to debate and needs further research. We 
should also bear in mind that patients who arrive at 
hospital many hours after injury are likely to diﬀ er from 
those who arrive early. For example, there could 
be an increased prevalence of hypothermia and 
acidosis. These or other diﬀ erences could explain the 
decreased eﬃ  cacy of tranexamic acid administration 
when given late.
A 2011 systematic review of randomised controlled 
trials concluded that tranexamic acid safely reduces 
mortality in bleeding trauma patients.12 Our results 
strongly endorse the importance of early administration 
of tranexamic acid in bleeding trauma patients and 
suggest that trauma systems should be conﬁ gured to 
facilitate this recommendation (panel). In patients 
presenting late (several hours after injury) the clinician 
should be more cautious and make an assessment of the 
individual beneﬁ ts and risks of this treatment, since the 
drug is likely to be much less eﬀ ective and possibly even 
harmful. To the extent that our subgroup analyses are 
consistent with the results of studies showing an early 
increased ﬁ brinolytic coagulopathy, they support the 
hypothesis that tranexamic acid acts through the 
inhibition of ﬁ brinolysis with improved haemostasis.
Future research using the CRASH-2 trial data will 
develop a prognostic model to predict death due to 
bleeding.13 This model will facilitate further analysis of 
the eﬀ ect of tranexamic acid according to baseline risk of 
haemorrhage death.
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Panel: Research in context
Systematic review 
A 2011 Cochrane systematic review12 of antiﬁ brinolytic drugs 
for acute traumatic injury identiﬁ ed two randomised trials of 
tranexamic acid in bleeding trauma patients, involving 
20 451 patients. The review concluded that tranexamic acid 
safely reduces mortality in bleeding trauma patients without 
increasing the risk of adverse events.
Interpretation
Our results emphasise the importance of early administration 
of tranexamic acid and the need for caution in patients 
presenting several hours after the injury.
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